These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 24408159)

  • 1. Outcomes and prognostic factors of first relapsed acute promyelocytic leukemia patients undergoing salvage therapy with intravenous arsenic trioxide and chemotherapy.
    Lou Y; Suo S; Tong Y; Tong H; Qian W; Meng H; Mai W; Huang J; Yu W; Jin J
    Ann Hematol; 2014 Jun; 93(6):941-8. PubMed ID: 24408159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
    Thirugnanam R; George B; Chendamarai E; Lakshmi KM; Balasubramanian P; Viswabandya A; Srivastava A; Chandy M; Mathews V
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia.
    Lou Y; Qian W; Meng H; Mai W; Tong H; Tong Y; Huang J; Jin J
    Hematol Oncol; 2014 Mar; 32(1):40-6. PubMed ID: 23963734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy.
    Cicconi L; Breccia M; Franceschini L; Latagliata R; Molica M; Divona M; Diverio D; Rizzo M; Ottone T; Iaccarino L; Alfonso V; Foa R; Voso MT; Lo-Coco F
    Ann Hematol; 2018 Oct; 97(10):1797-1802. PubMed ID: 29951912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: a bridge to transplantation.
    Leoni F; Gianfaldoni G; Annunziata M; Fanci R; Ciolli S; Nozzoli C; Ferrara F
    Haematologica; 2002 May; 87(5):485-9. PubMed ID: 12010661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide.
    Sanford D; Lo-Coco F; Sanz MA; Di Bona E; Coutre S; Altman JK; Wetzler M; Allen SL; Ravandi F; Kantarjian H; Cortes JE
    Br J Haematol; 2015 Nov; 171(4):471-7. PubMed ID: 26205361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term survival and prognostic study in acute promyelocytic leukemia treated with all-trans-retinoic acid, chemotherapy, and As2O3: an experience of 120 patients at a single institution.
    Hu J; Shen ZX; Sun GL; Chen SJ; Wang ZY; Chen Z
    Int J Hematol; 1999 Dec; 70(4):248-60. PubMed ID: 10643151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics and prognosis analysis of additional chromosome abnormalities in newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide as the front-line therapy.
    Lou Y; Suo S; Tong H; Ye X; Wang Y; Chen Z; Qian W; Meng H; Mai W; Huang J; Tong Y; Jin J
    Leuk Res; 2013 Nov; 37(11):1451-6. PubMed ID: 23958062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term survey of outcome in acute promyelocytic leukemia: a single center experience in 340 patients.
    Liu YJ; Wu DP; Liang JY; Qiu HY; Jin ZM; Tang XW; Fu CC; Ma X
    Med Oncol; 2011 Dec; 28 Suppl 1():S513-21. PubMed ID: 21069477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial.
    Zhu HH; Wu DP; Jin J; Li JY; Ma J; Wang JX; Jiang H; Chen SJ; Huang XJ
    J Clin Oncol; 2013 Nov; 31(33):4215-21. PubMed ID: 24127444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arsenic trioxide- and idarubicin-induced remissions in relapsed acute promyelocytic leukaemia: clinicopathological and molecular features of a pilot study.
    Kwong YL; Au WY; Chim CS; Pang A; Suen C; Liang R
    Am J Hematol; 2001 Apr; 66(4):274-9. PubMed ID: 11279639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia.
    Raffoux E; Rousselot P; Poupon J; Daniel MT; Cassinat B; Delarue R; Taksin AL; Réa D; Buzyn A; Tibi A; Lebbé G; Cimerman P; Chomienne C; Fermand JP; de Thé H; Degos L; Hermine O; Dombret H
    J Clin Oncol; 2003 Jun; 21(12):2326-34. PubMed ID: 12805334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data.
    Mathews V; George B; Chendamarai E; Lakshmi KM; Desire S; Balasubramanian P; Viswabandya A; Thirugnanam R; Abraham A; Shaji RV; Srivastava A; Chandy M
    J Clin Oncol; 2010 Aug; 28(24):3866-71. PubMed ID: 20644086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European acute promyelocytic leukemia group.
    de Botton S; Fawaz A; Chevret S; Dombret H; Thomas X; Sanz M; Guerci A; San Miguel J; de la Serna J; Stoppa AM; Reman O; Stamatoulas A; Fey M; Cahn JY; Sotto JJ; Bourhis JH; Parry A; Chomienne C; Degos L; Fenaux P
    J Clin Oncol; 2005 Jan; 23(1):120-6. PubMed ID: 15534358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of an acute promyelocytic leukemia relapse using arsenic trioxide and all-trans-retinoic in a 6-year-old child.
    Rock N; Mattiello V; Judas C; Huezo-Diaz P; Bourquin JP; Gumy-Pause F; Ansari M
    Pediatr Hematol Oncol; 2014 Mar; 31(2):143-8. PubMed ID: 24498972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of hematopoietic stem cell transplantation for relapsed acute promyelocytic leukemia: a retrospective analysis of JALSG-APL97.
    Fujita H; Asou N; Iwanaga M; Hyo R; Nomura S; Kiyoi H; Okada M; Inaguma Y; Matsuda M; Yamauchi T; Ohtake S; Izumi T; Nakaseko C; Ishigatsubo Y; Shinagawa K; Takeshita A; Miyazaki Y; Ohnishi K; Miyawaki S; Naoe T;
    Cancer Sci; 2013 Oct; 104(10):1339-45. PubMed ID: 23837667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention.
    Esteve J; Escoda L; Martín G; Rubio V; Díaz-Mediavilla J; González M; Rivas C; Alvarez C; González San Miguel JD; Brunet S; Tomás JF; Tormo M; Sayas MJ; Sánchez Godoy P; Colomer D; Bolufer P; Sanz MA;
    Leukemia; 2007 Mar; 21(3):446-52. PubMed ID: 17205057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High efficacy of arsenic trioxide plus all-trans retinoic acid based induction and maintenance therapy in newly diagnosed acute promyelocytic leukemia.
    Lou Y; Qian W; Meng H; Mai W; Tong H; Tong Y; Huang J; Jin J
    Leuk Res; 2013 Jan; 37(1):37-42. PubMed ID: 23017225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors of patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide-based frontline therapy.
    Lou Y; Ma Y; Suo S; Ni W; Wang Y; Pan H; Tong H; Qian W; Meng H; Mai W; Huang J; Yu W; Wei J; Mao L; Jin J
    Leuk Res; 2015 Sep; 39(9):938-44. PubMed ID: 26183877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic evaluation of arsenic trioxide compared to all-trans retinoic acid + conventional chemotherapy for treatment of relapsed acute promyelocytic leukemia in Canada.
    Lachaine J; Mathurin K; Barakat S; Couban S
    Eur J Haematol; 2015 Sep; 95(3):218-29. PubMed ID: 25354894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.